ClinConnect ClinConnect Logo
Search / Trial NCT06890533

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

Launched by SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. · Mar 21, 2025

Trial Information

Current as of April 23, 2025

Not yet recruiting

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent
  • 2. Body mass index (BMI) ≥18 kg/m2 and ≤28 kg/m2.
  • 3. ASA I - II
  • 4. Experiences a pain intensity rating of moderate to severe acute pain following abdominal surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery
  • Exclusion Criteria:
  • 1. Allergy to opioids and other medications that may be used during the trial.
  • 2. Nervous system disorders (e.g. epilepsy)
  • 3. Psychiatric disorders (e.g. depression)
  • 4. History of difficult airways
  • 5. Random blood glucose ≥11.1 mmol/L
  • 6. Uncontrolled blood pressure \[e.g., hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg),or hypotension(systolic blood pressure \<90 mmHg)\]
  • 7. Abnormal pulse oxygen saturation (SpO2 \<90 %)
  • 8. Abnormal liver function or renal function
  • 9. Used agents that could affect the analgesic response
  • 10. Used agents that could affect drug metabolism
  • 11. Has previously participated in another YZJ-4729 clinical study

About Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Shanghai Haiyan Pharmaceutical Technology Co., Ltd. is a leading biopharmaceutical company based in Shanghai, specializing in the research, development, and commercialization of innovative therapeutic solutions. With a commitment to advancing healthcare, the company focuses on a diverse range of therapeutic areas, including oncology, neurology, and infectious diseases. Leveraging cutting-edge technology and a robust pipeline of clinical trials, Shanghai Haiyan Pharmaceutical aims to deliver high-quality, effective treatments that address unmet medical needs while adhering to stringent regulatory standards. Through strategic collaborations and a dedication to scientific excellence, the company is positioned to make significant contributions to the global pharmaceutical landscape.

Locations

Zhengzhou, , China

Chongqing, , China

Chongqing, , China

Changsha, , China

Tianjin, , China

Wuhan, , China

Chengdu, , China

Xiamen, , China

Dongguan, , China

Zhuzhou, , China

Nanchang, , China

Guangzhou, , China

Xi'an, , China

Luoyang, , China

Shanghai, , China

Neijiang, , China

Dalian, , China

Deyang, , China

Cangzhou, , China

Ningbo, , China

Ch'ang Ch'un, , China

Jiaxing, , China

Cangzhou, , China

Hengyang, , China

Huzhou, , China

Liuzhou, , China

Guangzhou, , China

Shanghai, , China

Taizhou, , China

Wuxi, , China

Haikou, , China

Mianyang, , China

Wuhan, , China

Chengdu, , China

Guangzhou, , China

Ganzhou, , China

Ha'erbin, , China

Ma'anshan, , China

Changsha, , China

Yibin, , China

Changsha, , China

Changde, , China

Liuzhou, , China

Chengdu, , China

Guangyuan, , China

Hefei, , China

Nanning, , China

Qingdao, , China

Zhangzhou, , China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported